BRAF and melanoma: They show that in BRAF-mutated melanoma patients after 3 days of treatment with BRAF and MEK inhibitors there is a statistically significant increase in the number of CTCs bearing activated pErbB3 receptor as compared to CTCs before initiation of treatment (Figure 6A).